Investors take note: Antibe’s revolutionary pain drug is entering Phase 3 trials

MARKET ONE — Antibe currently has three assets in development for three blockbuster-scale indication.
  • Proprietary hydrogen sulfide drug platform poised to significantly change the way pain and inflammation is treated
  • Lead drug otenaproxesul has shown to dramatically reduce stomach ulcers compared to naproxen in clinical trials
  • In June 2020, Antibe reported positive top-line results from its Phase 2B dose ranging efficacy study designed to validate the efficacy of otenaproxesul in reducing pain
Hydrogen sulfide has come to be recognized as central to a wide range of key cellular functions.
The otenaproxesul molecule.
In 2018, Antibe completed a Phase 2B gastrointestinal safety trial of otenaproxesul in 244 healthy volunteers. The study was designed to demonstrate the superiority of otenaproxesul compared to naproxen, one of the most prescribed NSAIDs in the U.S.
As indicated in the diagram above, hydrogen sulfide plays several crucial roles in maintaining the health of the digestive system.
Antibe’s shares began trading on the TSX under its existing ticker symbol “ATE” on Thursday, November 12, 2020.
  • Announced robust secondary data from otenaproxesul’s Phase IIB dose-ranging, efficacy study, confirming the drug’s remarkable potency shown in earlier top-line results
  • Completed third party studies for the seven largest markets, framing an impressive commercial opportunity for otenaproxesul
  • Initiated two animal toxicology studies required for all companies by the U.S. Food and Drug Administration to begin Phase III trials (six additional such studies have commenced in the current quarter)
  • Launched pipeline expansion initiatives aimed at developing new intellectual property based on the company’s hydrogen sulfide platform
  • Commenced a proprietary naming initiative for otenaproxesul with a leading global branding agency to determine the commercial brand/trademark
  • Engaged Stern IR, a premier investor relations agency for healthcare and biotechnology companies worldwide, to support Antibe’s institutional outreach in the U.S.
  • Completed the quarter with a cash balance of $22.5 million

--

--

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Market One

Market One

Canada’s leading marketing agency for public companies.